share_log

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

Apellis Pharmaceuticals将于2024年8月1日举行电话会议,讨论2024年第二季度的财务业绩。
Apellis Pharmaceuticals ·  07/18 00:00

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second quarter 2024 financial results on Thursday, August 1, 2024, at 8:30 a.m. ET.

2024年7月18日,马萨诸塞州沃尔瑟姆(WALTHAm)(全球新闻通讯社)-- apellis pharmaceuticals今日,APLS公司(纳斯达克:APLS)宣布将于2024年8月1日星期四上午8:30(美国东部时间)举行电话会议和网络直播,讨论该公司2024年第二季度的财务业绩。

To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for 90 days following the event.

如欲通过电话收听实况,请预先注册。这里参与者还可以通过该公司网站“投资者与媒体”栏目下的“活动和展示文稿”页面获得活动的现场音频网络直播及幻灯片。网络直播重播将在活动结束后的90天内提供。

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.

关于Apellis
Apellis Pharmaceuticals是一家全球生物制药公司,结合勇敢的科学和同情心,为一些最具挑战性的疾病患者开发改变生命的治疗方案。我们推出了15年来第一个新的补体药物系,现有两种针对C3的批准药物,其中包括全球首款用于地理萎缩症的治疗。我们相信,我们才刚刚开始释放针对C3治疗严重眼部、罕见和神经系统疾病的潜力。欲了解更多信息,请访问或关注我们的Twitter和LinkedIn。

Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

投资者联系人:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178


声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发